American Association for Cancer Research
10780432ccr133231-sup-123355_2_supp_2483388_n5xpxq.docx (54.87 kB)

Data Supplement from Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH

Download (54.87 kB)
journal contribution
posted on 2023-03-31, 18:08 authored by David Wu, Ryan O. Emerson, Anna Sherwood, Mignon L. Loh, Anne Angiolillo, Bryan Howie, Jennifer Vogt, Mark Rieder, Ilan Kirsch, Christopher Carlson, David Williamson, Brent L. Wood, Harlan Robins

Supplementary Figure 1. Frequency of B cells with unique IGH rearrangements identified in bone marrow aspirates from 9 normal individuals. We performed multiplex PCR and sequencing to capture the IGH rearrangement repertoire present in the bone marrow samples of 9 healthy adults, and analyzed the frequency of the most common clones in each sample. The average frequency of the top clone was 0.8% of B cells, or ~0.08% of total nucleated cells. Above, the probability density of a normal distribution calculated using the geometric mean and standard deviation of top clone frequency is charted for this dataset.



Purpose: High-throughput sequencing (HTS) of immunoglobulin heavy-chain genes (IGH) in unselected clinical samples for minimal residual disease (MRD) in B lymphoblastic leukemia (B-ALL) has not been tested. As current MRD-detecting methods such as flow cytometry or patient-specific qPCR are complex or difficult to standardize in the clinical laboratory, sequencing may enhance clinical prognostication.Experimental Design: We sequenced IGH in paired pretreatment and day 29 post-treatment samples using residual material from consecutive, unselected samples from the Children's Oncology Group AALL0932 trial to measure MRD as compared with flow cytometry. We assessed the impact of ongoing recombination at IGH on MRD detection in post-treatment samples. Finally, we evaluated a subset of cases with discordant MRD results between flow cytometry and sequencing.Results: We found clonal IGH rearrangements in 92 of 98 pretreatment patient samples. Furthermore, while ongoing recombination of IGH was evident, index clones typically prevailed in MRD-positive post-treatment samples, suggesting that clonal evolution at IGH does not contribute substantively to tumor fitness. MRD was detected by sequencing in all flow cytometry–positive cases with no false-negative results. In addition, in a subset of patients, MRD was detected by sequencing, but not by flow cytometry, including a fraction with MRD levels within the sensitivity of flow cytometry. We provide data that suggest that this discordance in some patients may be due to the phenotypic maturation of the transformed cell.Conclusion: Our results provide strong support for HTS of IGH to enhance clinical prognostication in B-ALL. Clin Cancer Res; 20(17); 4540–8. ©2014 AACR.

Usage metrics

    Clinical Cancer Research



    Ref. manager